Qnovia

Executive Summary

Qnovia is a preclinical-stage drug delivery company developing a novel metered-dose inhaler platform designed to deliver a broad range of pharmaceuticals via the lung. Founded in 2019 and headquartered in Richmond, Virginia, the company aims to disrupt traditional inhaled therapies by enabling precise, consistent dosing of both small molecules and biologics. Qnovia's technology has potential applications in respiratory diseases (e.g., asthma, COPD), systemic conditions, and smoking cessation—particularly as an inhalable nicotine replacement therapy (NRT). While still early-stage (no disclosed pipelines or funding rounds), the platform's versatility positions it for multiple licensing or partnership opportunities. The company operates in a competitive space but differentiates through device simplicity and formulation flexibility. Near-term milestones include lead candidate selection, initial pharmacokinetic studies, and advancing toward IND-enabling activities. Given its early status, Qnovia carries high technical risk but significant upside if the platform validates across multiple indications.

Upcoming Catalysts (preview)

• TBDSeries A Financing Round70% success
• Q3 2026Lead Inhalable NRT Candidate Entering Preclinical Development60% success
• TBDStrategic Partnership with Respiratory Pharma Company40% success